Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.13, Iss.15, 2012-10, pp. : 2225-2232

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Delayed-Release Multi Matrix System (MMX™) Mesalazine: In Ulcerative Colitis

By McCormack Paul L. Robinson Dean M. Perry Caroline M.

Drugs, Vol. 67, Iss. 17, 2007-01 ,pp. : 2635-2642

Adis International

Access to resources Recommend Favorite

Budesonide multi-matrix system formulation for treating ulcerative colitis

By Prantera Cosimo Scribano Maria Lia

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 6, 2014-04 ,pp. : 741-743

Informa Healthcare

Access to resources Recommend Favorite

MMX® Mesalazine: A Review of its Use in the Management of Mild to Moderate Ulcerative Colitis

By Yang Lily P.H. McCormack Paul L.

Drugs, Vol. 71, Iss. 2, 2011-01 ,pp. : 221-235

Adis International

Access to resources Recommend Favorite

Delayed-Release Multi Matrix System (MMX™) Mesalazine in Ulcerative Colitis: A Viewpoint by Åke Nilsson

By Nilsson Åke

Drugs, Vol. 67, Iss. 17, 2007-01 ,pp. : 2643-2644

Adis International

Access to resources Recommend Favorite

Balsalazide: A Review of its Therapeutic Use in Mild-to-Moderate Ulcerative Colitis

By Muijsers R.B.R. Goa K.L.

Drugs, Vol. 62, Iss. 11, 2002-01 ,pp. : 1689-1705

Adis International

Access to resources Recommend Favorite